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Endometriosis is diagnosed when tissue 
which resembles the endometrial lining exists 
outside the endometrial cavity Although first 
described as a pathological entity in the late 
1800s, the term "endometriosis" was not in­
troduced until the early 1920s by Sampson ' 
The great volume of literature which has accu­
mulated on this topic is, by and large, a product 
of the 20th century. 
Many theories exist as to the histogenesis 
of endometriosis. All may be assigned to one of 
three basic groups in which 1) endometrial tis­
sue is transplanted ectopically as a result of re­
gurgitation, metastasis, or oviduct extension, 2) 
endometrial tissue develops ectopically in situ 
from local tissues, or 3) a combination of trans­
plantation and development in situ. Of the three 
groups, only the first has been documented; the 
other two are speculative.? 
Grossly, endometriosis often presents as 
purplish, dusky red, or brownish spots or ele­
vated nodules surrounded by varying degrees 
of fibrosis and scarring Typically it involves the 
peritoneal surface of the ovary or ovaries, cul­
de-sac, or bladder. Less frequently the bowel, 
appendix, bladder, ureters, cervix, vagina, and 
vulva are involved. Rarely, it is reported in the 
umbilicus, pleura, lungs, and extremities. Trans­
plantation into surgical incisions ot the abdomi­
nal wall and perineum has been documented. 
Microscopic evidence of endometriosis is 
not always clear-cut. One would like to see en­
dometrial-like epithelium, glands or gland-like 
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structures. and stroma accompanied by evi­
dence of hemorrhage. Not infrequently a picture 
"consistent with endometriosis" will present it­
self revealing hemosiderin, fibroblasts, and pig­
ment-laden macrophages However, one can­
not be secure in the pathological diagnosis if it 
is based solely on such evidence. 
Malignant degeneration occurring within 
areas of endometriosis is uncommon-less 
than 1 %. When it does occur, it is seen much 
more frequently in the glandular component as 
an adenocarcinoma than in the the stromal 
component; rarely is the malignancy of a mixed 
type Endometroid carcinoma of the ovary does 
not appear to be directly related in its histogen­
esis to endometriosis. 
Clinically, endometriosis is a disease of 
the reproductive years. Although it is being seen 
more frequently in teenagers, it has never been 
reported to occur before the menarche. The dis­
ease may pose a problem for the peri­
menopausal woman. 
The frequency with which endometriosis is 
reported to occur in a given population is highly 
variable. Perhaps as many as 20% to 25% of 
women 24-45 years old have some evidence of 
endometriosis recognizable at the time of lap­
aroscopy. It is being detected with increasing 
frequency in blacks, historically a group thought 
to have a very low incidence of the disease. 
The patient with endometriosis usually 
complains of secondary dysmenorrhea or pelvic 
pain, menstrual abnormalities, and frequently ol 
infertility 
The pain is highly variable and its severity 
often cannot be related to the extent of the dis­
ease. Pain usually begins some years after 
:nenarche and may be premenstrual or men­
strual in occurrence. Extensive endometriosis 
may be associated with chronic pain throughout 
the menstrual cycle. Sometimes the disease 
causes pelvic pressure or a sense of heaviness 
and fullness which the patient does not interpret 
as pain. Low backache and deep dyspareunia 
are usually the result of uterosacral involvement. 
Rectal and bladder tenesmus occurs and cyclic 
sciatica (Head sign) has been reported. 
Abormalities of menstruation consisting of 
hypermenorrhea and an irregular menstrual in­
terval imply ovarian involvement. Ten percent of 
patients with significant endometriosis have epi­
sodes of anovulation. As the disease is com­
monly associated with an increased incidence 
of endometrial polyps, leiomyomata, and ade­
nomyosis, these conditions must also be sus­
pect as causes of abnormal menstruation. 
Infertility may be the result of a number of 
factors: ovarian dysfunction, kinking of the ovi­
ducts, scarring of the fimbria, uterotubal spasm, 
and a decrease in coital exposure due to dyspa­
reunia and chronic pelvic discomfort. This prob­
lem becomes more perplexing, however, when 
one is reminded that most patients with endo­
metriosis ovulate, few have blocked tubal lu­
mens, and many have previously borne chil­
dren. 
The patient with complaints suggestive of 
endometriosis may or may not have the classic 
physical findings of pelvic tenderness, cul-de­
sac nodularity, organ fixation, or abnormal ad­
nexal masses. Many, with minimal endometrio­
sis, appear to offer the most complaints, 
whereas others, with extensive involvement, 
may appear relatively asymptomatic. There is 
yet another group in which endometriosis is only 
an incidental finding at the time of laparoscopy 
or laparotomy. 
Although the pelvic findings may confirm 
the suspicion of endometriosis, the diagnosis 
cannot be made unless the disease process is 
visualized or biopsied. Laparoscopy has proved 
invaluable in the diagnosis and ma�agement of 
patients suspected of having endometriosis. In­
dications for laparoscopy are given in Table 1. 
When endometriosis is encountered, diagrams 
of the extent of involvement should be entered 
in the patient's medical record. The Baylor 
classification of pelvic endometriosis is helpful 
in documenting findings and serving as a guide 
to medical and/or surgical therapy (Table 2).3 
TABLE 1 
Indications for Laparoscopy 
Severe unexplained pelvic pain 
Progressively severe dysmenorrhea 
Dyspareunia, especially with deep penetration 
Metrorrhagia uncontrolled by dilatation and curettage and/ 
or hormones 
Pelvic findings suggestive of endometriosis 
Unexplained infertility 
Medical management of endometriosis is 
aimed at the relief of pelvic discomfort and the 
preservation of the patient's childbearing poten­
tial. Initially, analgesics and heat may provide 
relief. The patient should be advised to avoid 
the continued use of narcotics and alcoholic 
beverages. It is best not to undertake the medi­
cal suppression of endometriosis using hor­
monal therapy unless the disease has been 
documented visually or by biopsy, and the ex­
tent of involvement determined. Hormonal ther­
apy is associated with many undesirable side 
effects and is expensive. Patients thought to 
have the disease but who in fact do not have it 
should be spared prolonged courses of hor­
monal therapy. 
Current hormonal regimens employ the 
TABLE 2 
Classification and Treatment 
MILD: Fresh implants. minimal scarring, no 
adhesions. minimal or no ovarian involve· 
ment 
Rx: Medical suppression­
Gestogens (pseudopregnancy) 
Danazol (pseudomenopause) 
Supportive therapy­
Analgesics. heat 
No therapy 
MODERATE: Implants with scarring and retraction, 
adhesions, endometrioma <2 cm, 
minimal peritubular and periovarian adhe­
sions 
Rx: Laparoscopic minisurgery 
Conservative surgery 
Medical suppression 
SEVERE: Endometrioma >2 cm, tube(s) and 
ovary or ovaries bound down by adhe­
sions. cul-de-sac obliteration. bowel or uri­
nary tract involvement 
Rx: Conservative surgery 
Hysterectomy with salpingo-oophorec­
tomy 
Medical suppression. postoperative. if 
indicated 
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gestogens to achieve pseudopregnancy or dan­
azol to achieve pseudomenopause Hormones 
appear to give the best results in the treatment 
of mild degrees of endometriotic involvement. 
They are capable of relieving pain and of reduc­
ing the extent of the disease to some degree; 
however. they are not likely to eliminate all foci 
of disease and thereby effect a cure. 
The gestogens, combinations of estrogen 
and progesterone, interrupt the negative feed­
back within the hypothalamic-pituitary-ovarian 
axis at the pituitary level. Follicle stimulating hor­
mone (FSH) and luteinizing hormone (LH) secre­
tions are suppressed. ovarian follicular develop­
ment and ovulation are inhibited. and the 
secretion of ovarian estrogen and progesterone 
is reduced. The inherent estrogenic and pro­
gestational properties of the gestogens initially 
stimulate endometrial growth and induce decid­
ual change within the endometrjal tissue. Sub­
sequently, amenorrhea and gradual atrophy of 
the uterine and ectopic endometrial tissue re­
sults in symptomatic relief. Pseudopregnancy 
regimens have been reported to provide symp­
tomatic relief in up to 94% of patients and a 
corrected pregnancy rate after treatment as 
high as 50%.'' The return of symptoms and the 
recurrence of endometriosis after therapy ap­
pear to increase progressively with the length of 
follow-up unless menopause ensues. The side 
effects of gestogen therapy include nausea, 
mastodynia, vaginal discharge, fluid retention, 
breakthrough bleeding, and on occasion, 
thromboembolism. Pseudopregnancy regimens 
should be avoided in patients with a history of 
thromboembolic disease and breast or endome­
trial carcinoma. 
Danazol, a weak synthetic testosterone, 
has antigonadotrophic properties similar to the 
gestogens. It is capable of inducing a pseudo­
menopausal state with its associated amenor­
rhea and endometrial atrophy but is unasso­
ciated with many of the undesirable side effects 
of gestogen therapy. Danazol suppresses FSH 
and LH secretion and therefore inhibits follicular 
development, ovulation, and corpus luteum for­
mation. Ovarian estrogen and progesterone se­
cretion is reduced to a minimum, causing endo­
metrial atrophy and amenorrhea. This inactivity 
and atrophy of ectopic endometrial tissue al­
lows reabsorption and healing Side effects of 
danazol therapy include the vasomotor symp­
toms of menopause, weight gain, edema, vagi-
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nal spotting, and acne. Fortunately, significanl 
androgenic effects are rare as the usual anti­
gonadotrophic dose required for the treatmenl 
of endometriosis is approximately one third thal 
capable of causing masculinization in the 
woman. Symptomatic improvement with thE 
danazol-pseudomenopausal regimen is re­
ported in up to 92% of patients Clinical im­
provement is noted in approximately 60% and 
a corrected pregnancy rate of 50% is said to 
exist. Unfortunately, the recurrence of symp­
toms is relatively high after discontinuance ol 
therapy. As with the pseudopregnancy regimen, 
conception after therapy prolongs the asympto­
matic interval. 
Moderate involvement with endometriosis 
is best treated with laparoscopic minisurgery fo, 
the lysis of adhesions, freeing of the ovaries, 
and cauterization of implants; a more extensive 
laparotomy may be required. Conservative sur­
gery, in cases of moderate and severe in­
volvement with endometriosis, is undertaken in 
an effort to correct reflux menstruation, relieve 
pelvic pain. and improve fertility. It consists pri­
marily of lysis of adhesions, the excision or de­
struction of all discernable endometriotic im­
plants and cysts, and is often accompanied by 
uterine suspension and presacral neurectomy in 
an effort to prevent subsequent retrofixation ol 
the uterus and provide relief of pelvic pain Con­
servative surgical approaches have been shown 
markedly to improve symptoms and child­
bearing potential. The addition of a pseudo­
pregnancy regimen to surgery, although recom­
mended by some, has in most cases not 
significantly added to the success of the opera, 
lion as measured by subsequent pregnancy o 
reducing the need for future surgery Approxi 
mately one quarter of patients undergoing con 
servative surgical therapy for endometriosis wil 
require future operative procedures because o 
endometriotic involvement. 5 
In severe cases of endometriotic in 
volvement, "radical" surgery, such as total ab 
dominal hysterectomy and bilateral salpingo· 
oophorectomy, may offer the only hope of c 
cure. II this is not an acceptable alternative fo1 
the particular patient, the physician should real­
istically think in terms of palliation rather than 
cure. The growth of ectopic endometrial tissu� 
cannot be permanently eradicated as long as 
functioning ovarian tissue remains within th� 
body Castration causes the involution an� 
death of active foci of endometriosis; however, 
the patient may still be left with fibrotic adhe­
sions and other residua which continue as a 
source of chronic pain. In selected cases, it 
may be advisable to follow a surgical approach 
to the treatment of endometriosis with a 
pseudopregnancy or pseudomenopausal regi­
men for the continued suppression of residual 
disease. 
Hormonal therapy for the surgically-in­
duced menopause may be required. If this can 
be anticipated, it is best to be sure that all foci 
of disease are removed at the time of surgery 
and not to depend upon castration alone to in­
activate residual disease. 11 au endometriosis 
has been removed, the patient may be started 
on conjugated equine estrogen. If it is thought 
that some endometriosis remains, it is best to 
delay hormonal therapy for six months or treat 
the patient for that period of time with me­
droxyprogesterone acetate; subsequently con-
jugated equine estrogen therapy may be insti­
tuted on a cyclic basis. 
Table 2 is adapted from Obstetrics and Gynecology 
(42: 19-25. 1973). 
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